Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

QA with Goodwins Andrew Harrow Exploring the Pharm

Stay informed with our article: Q&A with Goodwin’s Andrew Harrow: Exploring the Pharma Deals Outlook in 2021 and what this means for you.

Q&A with Goodwin’s Andrew Harrow: Exploring the Pharma Deals Outlook in 2021

Related Content

FDA approves CAR-T Cell Therapy for Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Corporate Transparency Act: January 1 Deadline is Almost Here

Amgen Files BPCIA Complaint Against Accord Biopharma Regarding Denosumab Biosimilar

Celltrion Launches STEQEYMA (ustekinumab) in Germany and the Netherlands

Life Sciences M&A Trends for 2023 and 2024 (Through End of Q3) in Greater China

FDA Accepts BLA for Shanghai Henlius Biotech’s and Organon’s HLX14, a Denosumab Biosimilar

Daewoong and Celltrion to Market Denosumab Biosimilar in Korea

EMA Accepts Marketing Authorization Application for Alvotech’s AVT05 (golimumab)

Goodwin advises Investor Consortium on Series B Financing of The Exploration Company

Goodwin Advises Biotheus in Agreement to be Acquired by BioNTech for $800 Million Upfront and $150 Million in Milestones

US & EP Data Exclusivity: Same Name, Different Games

Vesalius and GSK Form Multi-Target Strategic Alliance to Develop Treatments for Parkinson's Disease; Vesalius To Receive $80 Million Upfront And Up To $570 Million In Potential Milestones And Tiered Royalties

AlloVir and Kalaris Therapeutics to Merge

Goodwin Advises Anika on Strategic Update of Business with Sale of Arthrosurface

Best Lawyers Best Law Firms 2025 Names Goodwin Biotechnology and Life Sciences Law Firm of the Year for the Eighth Time and Recognizes 55 Practice Areas

The Guide to Life Sciences: FTC Pharma Scrutiny Expected to Continue Following Step Up in Killer Acquisition Enforcement (GCR)

Life Sciences